We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ALT Pemvidutide Explained: What Makes It Different in MASH
Read MoreHide Full Article
Key Takeaways
Altimmune's pemvidutide showed MASH resolution without worsening fibrosis in a phase IIb study.
ALT's dual glucagon and GLP-1 pathways aim to target liver fat, inflammation and weight loss together
ALT plans a 1,800-patient phase III MASH trial in 2026 with FDA-aligned endpoints for approval
Altimmune (ALT - Free Report) is advancing pemvidutide as a differentiated approach to serious liver diseases where effective options remain limited.
The key question for investors is whether pemvidutide’s dual-pathway biology and tolerability profile can hold up as ALT moves from encouraging mid-stage data into pivotal execution.
ALT’s Pipeline-in-a-Product Thesis
Pemvidutide is designed as a balanced 1:1 glucagon/GLP-1 dual receptor agonist. That equal activity is central to ALT’s “pipeline in a product” framing, which aims to address metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) with one core drug platform.
The thesis rests on pairing a liver-directed mechanism with a weight-loss pathway, targeting multiple disease drivers rather than treating a single dimension of MASH biology. ALT is also leaning into the high unmet need signaled by the FDA’s Fast Track designations in MASH and AUD, and Breakthrough Therapy Designation in MASH.
Altimmune’s Dual Pathway Rationale
ALT’s strategy splits the work between two hormone pathways that may complement each other in liver disease. Glucagon is described as working directly on the liver, with potential effects on reducing liver fat, inflammation, and scarring (fibrosis). That direct hepatic action is the core of why pemvidutide is being developed for progressive liver indications.
GLP-1, in contrast, is tied to appetite reduction and weight loss, with potential anti-inflammatory benefits. In ALT’s framing, combining glucagon’s liver effects with GLP-1’s metabolic impact could address multiple aspects of liver disease at once, including the contribution of excess weight to hepatic stress.
This dual-pathway positioning also shapes how investors may benchmark the asset versus GLP-1-only approaches and other MASH mechanisms. In the broader competitive landscape, Novo Nordisk (NVO - Free Report) and Eli Lilly (LLY - Free Report) have built leadership in incretin-based therapies, including marketed GLP-1 programs.
ALT’s EuPort Design and Tolerability Angle
Pemvidutide incorporates ALT’s proprietary EuPort technology, which is intended to slow absorption. The goal is improved tolerability, particularly by reducing common gastrointestinal side effects that can limit persistence on therapy.
ALT’s argument is practical: better tolerability can support longer treatment duration and adherence, which may matter in chronic liver diseases where sustained exposure could be important to achieve durable histologic and biomarker improvement.
Altimmune’s Phase IIb MASH Readout Takeaways
In the phase IIb MASH program, pemvidutide delivered statistically significant MASH resolution without worsening fibrosis at 24 weeks, with durability reported through 48 weeks.
ALT also highlighted “clear signs” of reduced scarring by 48 weeks. Non-invasive markers of fibrosis, including ELF and liver stiffness, were reported as significantly improved versus placebo, and the effect deepened from 24 to 48 weeks, supporting the company’s antifibrotic narrative.
Weight loss contributed as a metabolic tailwind, with meaningful reductions reported in the higher-dose group and continued weight reduction through 48 weeks without plateauing. Safety was described as favorable, with low discontinuation rates and no serious treatment-related adverse events.
ALT’s Phase III Setup and What FDA Alignment Signals
ALT expects to initiate a global phase III MASH study in 2026 focused on patients with moderate-to-severe liver fibrosis. The program is designed to support accelerated approval, using week 52 biopsy co-primary endpoints, with longer follow-up intended to support full approval.
The planned scope is approximately 1,800 patients across biopsy and non-invasive cohorts, with titration to 1.8 mg and 2.4 mg. Management has also stated it has secured manufacturing supply for a global phase III study, with a process that can be scaled further if needed.
ALT’s FDA alignment on key late-stage parameters, paired with Breakthrough Therapy Designation in MASH, strengthens the regulatory posture heading into pivotal execution. Still, the phase III proof bar in MASH remains high in a crowded field that includes THR-β agonists such as Madrigal Pharmaceuticals (MDGL - Free Report) with its FDA-approved resmetirom, and Viking Therapeutics with its liver-targeted THR-β program.
Altimmune’s Key Risks Investors Should Track
ALT is heavily dependent on a single asset. The downside is straightforward: if the phase III MASH study fails, the shares would likely be hit materially.
Competition is another major overhang across MASH, AUD, and ALD. In MASH, ALT is competing against GLP-1 drugs, GLP-1 combinations, FGF-21 therapies, THR-β agonists, and other emerging mechanisms being pursued by large players and focused biotechs. In ALD, competitors include programs spanning FGF-21, GLP-1, and RNA-based approaches. In AUD, pemvidutide faces established treatments such as Vivitrol and generics including naltrexone and acamprosate, alongside newer development efforts.
Finally, despite a cash runway projected into 2028 under current plans, management has indicated additional capital will likely be needed to fully fund phase III. That creates ongoing dilution and execution risk as spending rises with late-stage enrollment and global study operations.
View the Zacks #1 Rank List
Image: Bigstock
ALT Pemvidutide Explained: What Makes It Different in MASH
Key Takeaways
Altimmune (ALT - Free Report) is advancing pemvidutide as a differentiated approach to serious liver diseases where effective options remain limited.
The key question for investors is whether pemvidutide’s dual-pathway biology and tolerability profile can hold up as ALT moves from encouraging mid-stage data into pivotal execution.
ALT’s Pipeline-in-a-Product Thesis
Pemvidutide is designed as a balanced 1:1 glucagon/GLP-1 dual receptor agonist. That equal activity is central to ALT’s “pipeline in a product” framing, which aims to address metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) with one core drug platform.
The thesis rests on pairing a liver-directed mechanism with a weight-loss pathway, targeting multiple disease drivers rather than treating a single dimension of MASH biology. ALT is also leaning into the high unmet need signaled by the FDA’s Fast Track designations in MASH and AUD, and Breakthrough Therapy Designation in MASH.
Altimmune’s Dual Pathway Rationale
ALT’s strategy splits the work between two hormone pathways that may complement each other in liver disease. Glucagon is described as working directly on the liver, with potential effects on reducing liver fat, inflammation, and scarring (fibrosis). That direct hepatic action is the core of why pemvidutide is being developed for progressive liver indications.
GLP-1, in contrast, is tied to appetite reduction and weight loss, with potential anti-inflammatory benefits. In ALT’s framing, combining glucagon’s liver effects with GLP-1’s metabolic impact could address multiple aspects of liver disease at once, including the contribution of excess weight to hepatic stress.
This dual-pathway positioning also shapes how investors may benchmark the asset versus GLP-1-only approaches and other MASH mechanisms. In the broader competitive landscape, Novo Nordisk (NVO - Free Report) and Eli Lilly (LLY - Free Report) have built leadership in incretin-based therapies, including marketed GLP-1 programs.
ALT’s EuPort Design and Tolerability Angle
Pemvidutide incorporates ALT’s proprietary EuPort technology, which is intended to slow absorption. The goal is improved tolerability, particularly by reducing common gastrointestinal side effects that can limit persistence on therapy.
ALT’s argument is practical: better tolerability can support longer treatment duration and adherence, which may matter in chronic liver diseases where sustained exposure could be important to achieve durable histologic and biomarker improvement.
Altimmune’s Phase IIb MASH Readout Takeaways
In the phase IIb MASH program, pemvidutide delivered statistically significant MASH resolution without worsening fibrosis at 24 weeks, with durability reported through 48 weeks.
ALT also highlighted “clear signs” of reduced scarring by 48 weeks. Non-invasive markers of fibrosis, including ELF and liver stiffness, were reported as significantly improved versus placebo, and the effect deepened from 24 to 48 weeks, supporting the company’s antifibrotic narrative.
Weight loss contributed as a metabolic tailwind, with meaningful reductions reported in the higher-dose group and continued weight reduction through 48 weeks without plateauing. Safety was described as favorable, with low discontinuation rates and no serious treatment-related adverse events.
ALT’s Phase III Setup and What FDA Alignment Signals
ALT expects to initiate a global phase III MASH study in 2026 focused on patients with moderate-to-severe liver fibrosis. The program is designed to support accelerated approval, using week 52 biopsy co-primary endpoints, with longer follow-up intended to support full approval.
The planned scope is approximately 1,800 patients across biopsy and non-invasive cohorts, with titration to 1.8 mg and 2.4 mg. Management has also stated it has secured manufacturing supply for a global phase III study, with a process that can be scaled further if needed.
ALT’s FDA alignment on key late-stage parameters, paired with Breakthrough Therapy Designation in MASH, strengthens the regulatory posture heading into pivotal execution. Still, the phase III proof bar in MASH remains high in a crowded field that includes THR-β agonists such as Madrigal Pharmaceuticals (MDGL - Free Report) with its FDA-approved resmetirom, and Viking Therapeutics with its liver-targeted THR-β program.
Altimmune’s Key Risks Investors Should Track
ALT is heavily dependent on a single asset. The downside is straightforward: if the phase III MASH study fails, the shares would likely be hit materially.
Competition is another major overhang across MASH, AUD, and ALD. In MASH, ALT is competing against GLP-1 drugs, GLP-1 combinations, FGF-21 therapies, THR-β agonists, and other emerging mechanisms being pursued by large players and focused biotechs. In ALD, competitors include programs spanning FGF-21, GLP-1, and RNA-based approaches. In AUD, pemvidutide faces established treatments such as Vivitrol and generics including naltrexone and acamprosate, alongside newer development efforts.
Finally, despite a cash runway projected into 2028 under current plans, management has indicated additional capital will likely be needed to fully fund phase III. That creates ongoing dilution and execution risk as spending rises with late-stage enrollment and global study operations.
Altimmune has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Altimmune, Inc. Price and Consensus
Altimmune, Inc. price-consensus-chart | Altimmune, Inc. Quote